H1 Text Magenta Text

Click Continue below to leave the current site and be taken to a site maintained by a third party who is solely responsible for its content. Organon is providing this link to you only as a convenience; its inclusion does not imply the endorsement of the linked site by Organon.

Thank you for signing up. You’ll be hearing from us soon.

Send your patients a link to get started with the MyVTAMA™ Savings Program

*Required field

Sign up now to be among the healthcare professionals to learn more about the latest data, insights, and expert perspectives on VTAMA® (tapinarof) cream, 1%.

*Required field

Please provide your NPI and contact information below if you would like a Dermavant Sciences sales representative in your region to contact you or if you would like to request samples of VTAMA® (tapinarof) cream, 1%^†

*Required field

References: 1. VTAMA (tapinarof) cream, 1%. Prescribing Information. Organon; 2024. 2. Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457-465. 3. Simpson E, Silverberg JI, Bissonnette R, et al. Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to 2 years of age with moderate to severe atopic dermatitis. Oral presentation at: European Academy of Dermatology and Venereology; October 11-14, 2023; Berlin, Germany. 4. Organon DOF [ADORING 1&2 Pooled Posthoc; Jan 2025]. 5. Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, treatment response off-therapy, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 trial in adults and children down to 2 years of age with atopic dermatitis. Poster presented at: Fall Clinical Dermatology Conference; October 24-27, 2024; Las Vegas, NV. 6. Stein Gold L, Del Rosso J, Ehst BD, et al. Tapinarof cream 1% once daily was well tolerated for the treatment of adults and children down to 2 years of age with moderate to severe atopic dermatitis across two pivotal phase 3 trials. Poster presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA. 7. Organon DOF. ADORING Patient Images. 2024. 8. Organon DOF. DMVT-505-3103. 2024. 9. Hebert AA, Del Rosso J, Johnson SM, et al. Patient and parent/caregiver satisfaction with efficacy and cosmetic elegance of tapinarof cream 1% once daily in a long-term extension trial in adults and children down to age 2 years with atopic dermatitis. Poster presented at: Fall Clinical Dermatology Conference; October 24-27, 2024; Las Vegas, NV. 10. Silverberg JI, Boguniewicz M, Quintana FJ, et al. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review. J Allergy Clin Immunol. 2024;154(1):1-10. 11. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110-2119. 12. Sutter CH, Azim S, Wang A, et al. Ligand activation of the aryl hydrocarbon receptor upregulates epidermal uridine diphosphate glucose ceramide glucosyltransferase and glucosylceramides. J Invest Dermatol. 2023;143(10):1964-1972. 13. Organon DOF. The effect of GSK2894512 on the Th2 polarization of human CD4+  T cells and on IL-8 release from TLR2-stimulated keratinocytes. 2015. 14. Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012;166(4):853-860.